Year-over-year, this metric declined by 100.0%, from $9.98M to $0.00. Over 5 years (FY 2020 to FY 2025), Liability instruments measured at fair value shows a downward trend with a -100.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Increases often reflect rising market valuations of the underlying instruments, which may imply future cash outflows or dilution.
These are financial instruments or derivative liabilities that are revalued at each reporting date based on market condi...
Common in biotech and high-growth firms with complex financing or acquisition-related earn-outs.
other_liability_instruments_measured_at_fair_value| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $75.28M | $94.60M | $44.91M | $28.18M | $19.49M | $80.04M | $63.55M | $103.72M | $31.11M | $28.37M | $25.74M | $26.89M | $26.25M | $24.11M | $9.98M | $12.31M | $33.27M | $0.00 | $0.00 |
| QoQ Change | — | +25.7% | -52.5% | -37.3% | -30.9% | +310.8% | -20.6% | +63.2% | -70.0% | -8.8% | -9.3% | +4.5% | -2.4% | -8.2% | -58.6% | +23.3% | +170.3% | -100.0% | — |
| YoY Change | — | — | — | — | -74.1% | -15.4% | +41.5% | +268.1% | +59.7% | -64.6% | -59.5% | -74.1% | -15.6% | -15.0% | -61.2% | -54.2% | +26.7% | -100.0% | -100.0% |